filmov
tv
CRISPR Therapeutics CTX131 and its competition.
Показать описание
Greetings, fellow investors! Welcome back to ShareTreck. I'm Raj, and today, I am sharing my thoughts about CTX131 which is an allogenic CD70 CAR-T therapy. It does face competition from another Allogenic CD70 CAR-T that are in clinical trial , but it still has advantage - find out why?
JOIN THE CHANNEL AS A MEMBER:
Please check out the membership offering and join me in the exciting new chapter for ShareTreck, Thanks for your support so far and looking forward to much more. Use the link below to join or click on the Join button on the bottom left of your screen or copy the link below to your browser address bar and press enter.
The videos in this channel should not be construed as financial advice. Always make sure to do your own due diligence and research.
Please do not trade or invest based on this video. Information provided in this video is not investment advice and is for entertainment purposes only.
Disease and therapy details are derived from news articles and publications by companies or research organizations. I am not a doctor but am only facilitating dissemination of published information.
JOIN THE CHANNEL AS A MEMBER:
Please check out the membership offering and join me in the exciting new chapter for ShareTreck, Thanks for your support so far and looking forward to much more. Use the link below to join or click on the Join button on the bottom left of your screen or copy the link below to your browser address bar and press enter.
The videos in this channel should not be construed as financial advice. Always make sure to do your own due diligence and research.
Please do not trade or invest based on this video. Information provided in this video is not investment advice and is for entertainment purposes only.
Disease and therapy details are derived from news articles and publications by companies or research organizations. I am not a doctor but am only facilitating dissemination of published information.
0:08:04
CRISPR Therapeutics CTX131 and its competition.
0:03:39
Crispr Therapeutics CEO: Science in gene editing is moving at break-neck speed
0:09:14
Game Changer? CTX-131: Supercharged CAR T-Cell Therapy with Market Potential
0:10:15
CRISPR Therapeutics In-Depth UPDATE (CRSP Stock) Still #1?
0:13:24
CRISPR Therapeutics: Will This Gene Editing Giant Bounce Back?
0:03:01
CRISPR Therapeutics: A Deep Dive into Gene-Editing Innovations and opportunity
0:13:12
CRISPR Therapeutics: Should you buy now? Will CRSP Bounce Back?
0:08:27
CRISPR Therapeutics CTX211 and why CRSP now has an advantage with this therapy.
0:07:05
CRISPR: CTX112 will be best of class and how that matters to investors?
0:14:36
Selling CRISPR Therapeutics Stock (CRSP)? Fundamentals or Fear | Innovation Day 2022
0:10:00
CRISPR Therapeutics: 5 reasons why I have high conviction to invest in CRSP stock
0:06:32
CRISPR Therapeutics (CRSP) - Despite equity dilution announcement, why did jump 8% today? Subtitled
0:24:58
Crispr Therapeutics: Sandeep discusses with Raj
0:07:33
Encouraging data from CRISPR Therapeutics
0:15:45
CRISPR Monthly Summary | CRSP Stock, BEAM, NTLA, VERV & more!
0:14:58
Is Crispr Therapeutics undervalued. Here is my short term price target and Justification.
0:11:38
Crunching The Numbers: Analyzing Crispr Therapeutics' Upcoming Quarterly Earnings Report
0:10:26
CRISPR Therapeutics CTX112 and FDA warnings on CD19 CAR-T. Indian breakthrough in low cost CAR-T.
0:26:15
Why CRSP's Sickle Cell Disease Therapy Is The Start of A Revolution (Trillion-Dollar Opportunit...
0:12:58
CRISPR Earnings UPDATE! (CRSP Stock, VERV, BEAM and beyond)
0:07:08
Post Earnings: How good is CRISPR Therapeutics (CRSP) post 2023 Earnings ? (with subtitles)
0:17:56
CRSP Stock News: Innovation Day Analysis
0:21:50
CRISPR Therapeutics: Is it time to buy? Why is the stock falling?
0:14:01
CRISPR Therapeutics: Strategy 2024 promises 18 months of catalysts and much more- need to watch!
Комментарии